ASH 2021 – Focused on CLL, MCL, and WM

The American Society of Hematology Annual Meeting (ASH) annual meeting is the premier event in malignant and non-malignant hematology. The 2021 annual meeting is taking place December 11-14, virtually and in-person in Atlanta, Georgia. The program provides attendees with insights into the latest advances in hematology.

Look out for coverage of the meeting and click here to learn more about the 2021 ASH Annual Meeting.

female home nurse supporting senior woman in using mobility walker at home.

Study Finds First-Line Targeted Treatment for CLL Is Beneficial in Elderly Patients

Although individuals older than 80 years make up more than 20% of cases of chronic lymphocytic leukemia (CLL), this...

Rituximab, Bendamustine, and Bortezomib Combination Improves Responses in Relapsed/Refractory Waldenström Macroglobulinemia

Second-line therapy comprising standard rituximab plus bendamustine and bortezomib was effective and well-tolerated as a salvage treatment option for...

Study Investigates Patient Preferences in Waldenström Macroglobulinemia Treatment

A mixed-method study of Dutch patients, presented at the 63rd American Society of Hematology Annual Meeting & Exhibition, examined...

Frontline Rituximab-Bendamustine Combination Shows Sustained Efficacy in Older MCL Patients

At the 2021 American Society of Hematology (ASH) Annual Meeting, researchers presented long-term follow-up data from a phase II...

Assessing Costs and Resource Utilization of Hospital-Based Care Among Patients with B-Cell Malignancies

Patients with mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL) have high...

Study Validates IMWG Frailty Scoring in Relapsed/Refractory Multiple Myeloma

At the 2021 American Society of Hematology Annual Meeting and Exposition, Fabio Efficace, PhD, and a team of researchers...

Pirtobrutinib in Patients with Previously Treated Mantle Cell Lymphoma

According to updated data from the phase I/II BRUIN study, presented at the 2021 American Society of Hematology Annual...
Long-term Night Shift Work Linked with Risk for Atrial Fibrillation and Coronary Heart Disease

Real-World Experience With Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma

Following its FDA approval in 2020 based on results from the ZUMA-2 trial, brexucabtagene autoleucel (brexu-cel) has been implemented...

Patients with Multiple Myeloma and Waldenström Macroglobulinemia Have Impaired COVID-19 Vaccine Responsiveness

According to a poster presented at the 2021 ASH Annual Meeting by Andrew R. Branagan, MD, PhD, and colleagues,...

Curated Journal Abstracts

Advertisement
Advertisement